Jefferies lowered the firm’s price target on Alnylam (ALNY) to $549 from $550 and keeps a Buy rating on the shares. The firm notes Q3 sales were strong, driven by rapid Amvuttra uptake for CM. Management commented “broad” access and uptake across tx naive and stabilizer progressors in academic plus community centers and with an expanded prescriber base. Jefferies further points out that Alnylam increased 2025 TTR revenue guidance substantially. For pipeline, obesity, CNS, and bleeding disorders data expected in 2026.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY:
- Alnylam Pharma: Strong Sales Growth and Financial Performance Justify Buy Rating
- Alnylam reports Q3 EPS $1.84, consensus $1.75
- ALNY Upcoming Earnings Report: What to Expect?
- Alnylam Pharmaceuticals: Strong Market Performance and Promising Pipeline Drive Buy Rating
- Alnylam’s ZENITH Study: A New Horizon in Cardiovascular Treatment